Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by Japan Patent Office.

Guangdong Raynovent Biotech Co.,Ltd received the ethical approval from The First Hospital of Jilin University for its phase 1b/2a clinical trial of Category 1 Drug ZSP1601, which is being developed for the treatment of NASH. Principal InvestigatorS of this clinical trial are Professor Junqi Niu and Yanhua Ding.

Guangdong Raynovent Biotech Co.,Ltd received the ethical approval from The First Affiliated Hospital of Guangzhou Medical University for its phase 2 clinical trial of ZSP1273, a Category 1 drug which is being developed for the prevention and treatment of influenza A and human avian influenza. Principal Investigator of this clinical trial is Academician Nanshan Zhong.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by IP Australia.

Raynovent received the Certificate of Invention Patent (Hydroxyl purine compounds and applications) issued by Canadian Intellectual Property Office.